Juliet Singh

Juliet Singh has served as the President and Chief Executive Officer of Transdel
Pharmaceuticals, Inc. since 2005. Prior to Transdel, Dr. Singh was a corporate
officer-Vice President of Regulatory Affairs and Quality Assurance of Collateral
Therapeutics, Inc. Dr. Singh also served as the Director of Worldwide Regulatory
affairs for Allergan Corporation, where she oversaw the registration of BOTOX
in the United States, Canada, Europe, Asia, and other regions. Prior to joining
Allergan, Dr. Singh was the Assistant Director of Regulatory Affairs for Baxter
Healthcare Corp., where she provided leadership in obtaining worldwide
regulatory approval for recombinant factor VIII.